1,000+ Opportunities

Find the right grant

Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.

ActiveNational Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA) · 2026

PHS 2024-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)

Quick Facts

Agency: National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA)
Funding: Phase I: ~$300k for 6–12 months; Phase II: ~$2M+ for up to 2 years (varies, check specific NIH Institute/Center for waivers beyond typical caps)
Deadline: Check Source
Status: Active
Eligibility: For-profit companies with fewer than 500 employees, majority-owned and controlled by U. S. citizens or permanent residents. Research must be conducted in the U. S.

About This Grant

PHS 2024-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed) is sponsored by National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA). This omnibus solicitation invites eligible United States small business concerns (SBCs) to submit Small Business Innovation Research (SBIR) grant applications for Phase I and Phase II.

View Original RFP

Get alerted about grants like this

Save a search for “National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA)” or related topics and get emailed when new opportunities appear.

Search similar grants →

Official Opportunity Details

Extracted from the official opportunity page/RFP to help you evaluate fit faster.

Opportunity Listing - PHS 2024-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed) PHS 2024-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed) Agency: National Institutes of Health Assistance Listings: 93.

143 -- NIEHS Superfund Hazardous Substances_Basic Research and Education 93. 142 -- NIEHS Hazardous Waste Worker Health and Safety Training 93. 865 -- Child Health and Human Development Extramural Research 93.

307 -- Minority Health and Health Disparities Research 93. 113 -- Environmental Health 93. 213 -- Research and Training in Complementary and Integrative Health 93.

837 -- Cardiovascular Diseases Research 93. 859 -- Biomedical Research and Research Training 93. 846 -- Arthritis, Musculoskeletal and Skin Diseases Research 93.

840 -- Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders 93. 350 -- National Center for Advancing Translational Sciences 93. 242 -- Mental Health Research Grants 93.

361 -- Nursing Research 93. 273 -- Alcohol Research Programs 93. 879 -- Medical Library Assistance 93.

279 -- Drug Abuse and Addiction Research Programs 93. 172 -- Human Genome Research 93. 121 -- Oral Diseases and Disorders Research 93.

394 -- Cancer Detection and Diagnosis Research 93. 847 -- Diabetes, Digestive, and Kidney Diseases Extramural Research 93. 395 -- Cancer Treatment Research 93.

173 -- Research Related to Deafness and Communication Disorders 93. 855 -- Allergy and Infectious Diseases Research 93. 867 -- Vision Research 93.

351 -- Research Infrastructure Programs 93. 393 -- Cancer Cause and Prevention Research 93. 839 -- Blood Diseases and Resources Research 93.

233 -- National Center on Sleep Disorders Research 93. 838 -- Lung Diseases Research 93. 286 -- Discovery and Applied Research for Technological Innovations to Improve Human Health 93.

853 -- Extramural Research Programs in the Neurosciences and Neurological Disorders Last Updated: April 1, 2025 View version history on Grants.

gov This Notice of Funding Opportunity (NOFO), issued by the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), and the Food and Drug Administration (FDA), invites eligible United States small businesses to submit Small Business Innovation Research (SBIR) grant applications.

United States small businesses that have the research capabilities and technological expertise to contribute to the R and D mission(s) of the NIH, CDC, and FDA awarding components identified in this NOFO are encouraged to submit SBIR grant applications in response to identified topics (see SBIR/STTR Program Descriptions and Research Topics for NIH, CDC, and FDA).

This Parent Funding Opportunity Announcement does not accept clinical trials. Other Eligible Applicants include the following:Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.

Foreign components, as defined in the NIH Grants Policy Statement, may be allowed. Grantor contact information See Section VII. Agency Contacts within the full opportunity announcement for all other inquires.

File name Description Last updated PA-24-245-Full-Announcement. html PA-24-245 Full Announcement Text Link to additional information https://grants. nih.

gov/grants/guide/pa-files/PA-24-245. html Archived: October 5, 2025 Funding opportunity number : Cost sharing or matching requirement : Funding instrument type : Opportunity Category Explanation : Category of Funding Activity : Income security and social services

Eligibility Requirements

For-profit companies with fewer than 500 employees, majority-owned and controlled by U. S. citizens or permanent residents. Research must be conducted in the U. S.

Frequently Asked Questions

Who can apply for PHS 2024-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)?

Based on current listing details, eligibility includes: For-profit companies with fewer than 500 employees, majority-owned and controlled by U. S. citizens or permanent residents. Research must be conducted in the U. S. Applicants should confirm final requirements in the official notice before submission.

What is the typical funding level for PHS 2024-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)?

Current published award information indicates Phase I: ~$300k for 6–12 months; Phase II: ~$2M+ for up to 2 years (varies, check specific NIH Institute/Center for waivers beyond typical caps) Always verify allowable costs, matching requirements, and funding caps directly in the sponsor documentation.

When is the deadline for PHS 2024-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)?

The current target date is rolling deadlines or periodic funding windows. Build your timeline backwards from this date to cover registrations, approvals, attachments, and final submission checks.

How competitive is PHS 2024-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)?

Federal grant success rates typically range from 10-30%, varying by agency and program. Build a strong proposal with clear objectives, measurable outcomes, and a well-justified budget to improve your chances.

What documents are required for PHS 2024-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)?

Requirements vary by sponsor, but typically include a project narrative, budget justification, organizational capability statement, and key personnel CVs. Check the official notice for the complete list of required attachments.

Can I use AI to write this grant proposal?

Yes — AI tools like Granted can help research funders, draft proposal sections, and check compliance. However, always review and customize AI-generated content to reflect your organization's unique strengths and the specific requirements of the solicitation.

How long does the review process take for PHS 2024-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)?

Review timelines vary by funder. Federal agencies typically take 3-6 months from submission to award notification. Foundation grants may be faster, often 1-3 months. Check the program's timeline in the official solicitation for specific dates.

Is PHS 2024-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed) renewable?

Many federal programs offer multi-year funding or allow competitive renewals. Check the official solicitation for continuation and renewal policies. Non-competing continuation applications are common for multi-year awards.

Funder Profile

Ready to start your proposal?

Granted drafts, reviews, and strengthens your grant application — saving weeks of work. Win a grant in 12 months or get a full refund.

Browse More Grants

Backed by the Granted Guarantee — win a grant or get a full refund.

VerifiedActive

PHS 2024-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)

PHS 2024-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed) is sponsored by National Institute on Minority Health and Health Disparities (NIMHD), National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA). NIMHD, through the NIH SBIR/STTR program, allocates grant funding for small businesses working with communities experiencing health and/or healthcare disparities.

See official notice (NIMHD encourages contacting a program official for awards exceeding standard amounts)Deadline: Check Source

National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA)

DiscoveredActive

PHS 2023-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)

PHS 2023-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed) is sponsored by National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA). This omnibus solicitation supports research and development projects in biomedical informatics and data science, including AI techniques for characterizing and minimizing errors in health-related datasets, novel platforms for integrating patient data, and technological approache…

Deadline: Check Source

ActiveNational Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA) · 2026

PHS 2024-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)

Quick Facts

Agency: National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA)
Funding: Phase I: ~$300k for 6–12 months; Phase II: ~$2M+ for up to 2 years (varies, check specific NIH Institute/Center for waivers beyond typical caps)
Deadline: Check Source
Status: Active
Eligibility: For-profit companies with fewer than 500 employees, majority-owned and controlled by U. S. citizens or permanent residents. Research must be conducted in the U. S.